The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Recent publication on the impact of response to lymphodepletion on PFS in NHL
Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses his recent research into the impact of response to lymphodepletion on PFS in non-Hodgkin lymphoma (NHL). This revealed that LDH, MCP-1, and IL-7 are independently associated with PFS in patients with aggressive NHL after CD19 CAR T-cell therapy. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
